文献速递白血病MDS 与骨髓增殖性肿瘤

Nf1与Sh2b3突变在幼年型粒单核细胞白血病小鼠模型中协同作用

Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia.
PubMed 文献 · Blood Adv · 2021-01-01

幼年型粒单核细胞白血病(JMML)由激活Ras信号的体细胞突变起始,部分患者携带额外继发突变,与移植后复发或转化为急性髓系白血病风险增加相关。本研究探讨继发SH2B3突变的影响,发现携带SH2B3突变的患者预后不良,外周血白细胞计数和血红蛋白F水平更高;在基因工程小鼠中,Sh2b3缺失与条件性Nf1缺失呈剂量依赖性协同,Sh2b3单倍剂量不足加重骨髓增殖性疾病严重程度。

要点

  • JMML患者中SH2B3突变与不良结局相关,外周血白细胞计数和血红蛋白F水平更高。
  • 小鼠中Sh2b3缺失与Nf1缺失呈剂量依赖性协同,Sh2b3单倍剂量不足加重骨髓增殖性疾病。
  • 该模型为高风险JMML患者治疗测试提供了实验系统。

核心结论

  • SH2B3继发突变与JMML患者不良结局相关,Sh2b3单倍剂量不足在小鼠中与Nf1缺失协同加重骨髓增殖性疾病。

研究设计与样本

  • 研究分析JMML患者中SH2B3突变的影响,并在基因工程小鼠中验证Sh2b3与Nf1缺失的相互作用。

主要发现

  • 携带SH2B3突变的JMML患者预后不良,外周血白细胞计数和血红蛋白F水平更高。
  • 小鼠中Sh2b3缺失与条件性Nf1缺失呈剂量依赖性协同,Sh2b3单倍剂量不足加重骨髓增殖性疾病严重程度。

临床怎么用

  • SH2B3突变可能作为JMML风险分层标志,该小鼠模型可用于测试高风险JMML患者的治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Juvenile myelomonocytic leukemia (JMML) is initiated in early childhood by somatic mutations that activate Ras signaling. Although some patients have only a single identifiable oncogenic mutation, others have 1 or more additional alterations. Such secondary mutations, as a group, are associated with an increased risk of relapse after hematopoietic stem cell transplantation or transformation to acute myeloid leukemia. These clinical observations suggest a cooperative effect between initiating and secondary mutations. However, the roles of specific genes in the prognosis or clinical presentation of JMML have not been described. In this study, we investigate the impact of secondary SH2B3 mutations in JMML. We find that patients with SH2B3 mutations have adverse outcomes, as well as higher white blood cell counts and hemoglobin F levels in the peripheral blood. We further demonstrate this interaction in genetically engineered mice. Deletion of Sh2b3 cooperates with conditional Nf1 deletion in a dose-dependent fashion. These studies illustrate that haploinsufficiency for Sh2b3 contributes to the severity of myeloproliferative disease and provide an experimental system for testing treatments for a high-risk cohort of JMML patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Morales CE, Stieglitz E, Kogan SC, et al. Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia. Blood Adv. 2021. PMID: 34464969. doi:10.1182/bloodadvances.2020003754

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。